

Infant RSV Immunization



Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization among infants in the United States. Fortunately, there are two ways to protect infants: maternal RSV vaccination (Abrysvo) and the long-acting infant RSV monoclonal antibody immunization (Beyfortus or Enflonsia). Most infants need either maternal vaccination or the infant monoclonal antibody immunization, not both. Below is more information about the infant monoclonal antibody immunizations.

Administration and Dosage

Monoclonal antibodies are administered between **October 1 and March 31**.

Beyfortus is administered as intramuscular injection (IM).

<8 months of age

<5 kg (11 lb): 50 mg

≥5 kg (11 lb): 100 mg

8–19 months of age

200 mg (administered as two 100 mg IM injections)

Enflonsia is administered as intramuscular injection (IM)

<8 months of age

105 mg

Both products are safe and effective, product choice should be guided by availability and patient preference.

Coadministration

Monoclonal antibodies can be administered with vaccines, including Hepatitis B and other routine childhood vaccines.

What are the Infant Monoclonal Antibodies?

There are two infant monoclonal antibody immunizations, Beyfortus (nirsevimab) or Enflonsia (clesrovimab). They are long-acting monoclonal antibodies. The antibodies themselves protect infants against severe RSV disease.

Age for Immunization

- Beyfortus or Enflonsia are administered to all infants <8 months of age.
 - Administered in the first week of life, ideally during birth hospitalization
 - Administered to eligible infants born April-September
- Beyfortus is administered to select children 8–19 months of age who are at increased risk of severe RSV disease.*

*American Indian and Alaska Native children; children who are severely immunocompromised; children with cystic fibrosis with severe disease; and children with chronic lung disease of prematurity who require medical support during the six months before the start of their second RSV season should receive Beyfortus during their second RSV season.

